Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neoadjuvant chemotherapy for bladder cancer.

Randall Millikan1, Arlene Siefker-Radtke, H Barton Grossman

  • 1Department of Genitourinary Medical Oncology, Genitourinary Center, University of Texas, M.D. Anderson Cancer Center, Houston, TX 77033, USA. rmillika@mdanderson.org

Urologic Oncology
|December 25, 2003
PubMed
Summary

Chemotherapy improves outcomes for select muscle invasive bladder cancer patients. A new biologically-based staging system is needed to guide treatment selection for this heterogeneous cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program.

The oncologist·2026
Same author

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

CA: a cancer journal for clinicians·2025
Same author

Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study.

European urology oncology·2025
Same author

The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder.

Advances in anatomic pathology·2025
Same author

The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms.

The American journal of surgical pathology·2025
Same author

Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.

Human pathology·2024

Area of Science:

  • Oncology
  • Urologic Oncology
  • Cancer Biology

Background:

  • Muscle invasive bladder cancer (MIBC) is a heterogeneous disease.
  • Chemotherapy offers improved outcomes for some MIBC patients.
  • Current staging lacks criteria for optimal patient selection for chemotherapy.

Purpose of the Study:

  • To advocate for a biologically-based staging system for MIBC.
  • To emphasize the need for improved patient selection for perioperative chemotherapy.

Main Methods:

  • Review of current MIBC treatment paradigms.
  • Analysis of MIBC heterogeneity.
  • Discussion of biologically-based versus anatomical staging.

Main Results:

Related Experiment Videos

  • Chemotherapy is beneficial in MIBC but patient selection remains a challenge.
  • Anatomical staging is insufficient for guiding chemotherapy decisions.
  • A biologically-based staging system is proposed as a solution.

    • Conclusions:

    • A biologically-based staging system is crucial for optimizing MIBC treatment.
    • Perioperative chemotherapy with standard combinations should be considered with curative intent.
    • Further research into MIBC biomarkers is warranted for improved patient stratification.